Sanofi Pasteur
 
Indication and Important Safety Information
See full Prescribing Information for Flublok® Quadrivalent Influenza Vaccine,
Fluzone® Quadrivalent Influenza Vaccine, or Fluzone® High-Dose Influenza Vaccine
 
View in browser
 
New this year, you have more ways to take control of your influenza vaccine reservations. Ordering directly through Sanofi Pasteur offers the most flexibility, allowing you to optimize your influenza vaccine scheduling. With direct ordering, you can:
- Create and manage your influenza vaccine shipment schedule
- Manage your inventory with customized order sizes and shipment frequency
 

How it works:

 
choose your PREFERRED shipment frequency on your reservation to autopopulate your shipments for each presentation:
- Once per week
- Twice per month
- Once per month
- Same as previous season
 
Review your selection and adjust if necessary. Even after you’ve scheduled your shipments, you can continue to customize your reservation by updating your shipments as needed until June 14, 2019.
 
CTA
 
 
Indication for Flublok Quadrivalent, Fluzone Quadrivalent, and Fluzone High-Dose Vaccines
 
Flublok Quadrivalent, Fluzone Quadrivalent, and Fluzone High-Dose vaccines are indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus(es) contained in each vaccine. Flublok Quadrivalent vaccine is approved for use in persons 18 years of age and older. Fluzone Quadrivalent vaccine is approved for use in persons 6 months of age and older. Fluzone High-Dose vaccine is approved for use in persons
65 years of age and older.
 
 
IMPORTANT SAFETY INFORMATION FOR FLUBLOK QUADRIVALENT, FLUZONE QUADRIVALENT, AND FLUZONE HIGH-DOSE VACCINES
 
Flublok Quadrivalent, Fluzone Quadrivalent, and Fluzone High-Dose vaccines should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose vaccines) or after a previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose vaccines should not be administered to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine.
 
If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent, Fluzone Quadrivalent, or Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks.
 
In adults, the most common local and systemic adverse reactions to Flublok Quadrivalent, Fluzone Quadrivalent, and Fluzone High-Dose vaccines include pain at the injection site; headache and myalgia. In children, the most common reactions to Fluzone Quadrivalent vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, and headache (irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever in young children). Other adverse reactions to these vaccines may occur. Vaccination with Flublok Quadrivalent, Fluzone Quadrivalent, or Fluzone High-Dose vaccine may not protect all individuals.
 
Before administration, please see the full Prescribing Information for Flublok Quadrivalent, Fluzone Quadrivalent, or Fluzone High‑Dose vaccine.
 

SANOFI PASTEUR. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofipasteur.us
SAUS.SFLU.19.03.1890                            ® 2019 Sanofi Pasteur Inc.                               4/19

sanofi pasteur